Skip to main content
Clinical Trials/NCT03377920
NCT03377920
Unknown
Not Applicable

Predictive Value of Peak Inspiratory Flow Rate Derived From Spirometry to Determine the Patient's Ability to Produce Peak Inspiratory Flow Rate to Overcome the Resistance of Current Dry Powders Inhalers.

Universitair Ziekenhuis Brussel1 site in 1 country100 target enrollmentOctober 12, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Severe Asthma
Sponsor
Universitair Ziekenhuis Brussel
Enrollment
100
Locations
1
Primary Endpoint
PIFspiro
Last Updated
8 years ago

Overview

Brief Summary

The main aim is to study correlations between Peak inspiratory flow measured during a spirometry (PIFspiro) and Peak inspiratory flow measured over a pre-set resistance (PIFresist) in COPD patients and severe asthma patients. PIFresist will be measured using 5 different resistances, representing all DPI's relevant for the treatment of obstructive lung diseases. If this shows a distinct relationship between PIFspiro and PIFresist, PIFspiro cut-off points will be sought in an attempt to predict which patients are likely to be able to produce optimal flows for DPI use. If successful, this will make the actual measurement of PIFresist redundant in clinical practice. Also the relationship between PIFresist and device internal resistance in addition to PIFspiro (which corresponds to a very low resistance) will be examined.

Detailed Description

The correct use of dry powder inhalers (DPI) crucially depends on the peak inspiratory flow (PIF) that the patient can generate when overcoming internal resistance of the inhaler device. It has been shown that some patients cannot achieve sufficient peak inspiratory flows with some DPI's, especially in the elderly population. The In-check Dial device (Clement Clarke International Ltd, Harlow, UK) allows to measure these inspiratory flows for different pre-set resistances, representing different DPI's. Study design: interventional, single center, single visit study 30 Severe asthmatics and 70 COPD patients will be recruited in the UZ Brussel respiratory outpatient clinic. All participants will provide written informed consent. Patients will perform: * pre-bronchodilator spirometry for the measurement of PIFspiro as per European respiratory Society/American Thoracic Society (ERS/ATS) guidelines for standard lung function5 (part of routine clinical follow-up). * 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's

Registry
clinicaltrials.gov
Start Date
October 12, 2017
End Date
September 2019
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Severe asthmatics (M/F; \> 20 y) entering the Belgian Severe Asthma Registry (BSAR)
  • COPD patients (GOLD stage II-IV; M/F; \> 40 y)

Exclusion Criteria

  • Inability to perform spirometry

Outcomes

Primary Outcomes

PIFspiro

Time Frame: At inclusion (D0)

PIFspiro (L/s): PIF measurement from standardized spirometry (3 flow-volume measurements);

PIFresist

Time Frame: At inclusion (D0)

PIFresist (L/min): PIF from In-check Dial (5 flow measurements with flow restrictor in 5 different positions)

Study Sites (1)

Loading locations...

Similar Trials